Title: Efficacy & Acceptibility of Azilsartan as Antihypertensive: A Clinical Evaluation in Magadh Zone of Bihar
Authors: Dr Pramod Kumar Sinha, Dr Neeraj Kumar
DOI: https://dx.doi.org/10.18535/jmscr/v6i2.17
Abstract
Introduction: Better control of hypertension while maintaining good quality of life with least side effect has always been the aim of antihypertensive therapy. Search for newer drugs continues and azilsartan has come up with so claimed improved quality.
Aims and Objectives: To study the so claimed improved quality of azilsartanin terms of efficacy and acceptability.
Material and Method: 2 doses of azilsartan (40 & 80 mg) is compared with 40 mg of olmesartan. 111 patients enrolled from the outdoor patients of Anugrah Narayan Medical College Hospital, Gaya randomized to three groups and clinic BP measurements recorded and analysed.
Results: Azilsartan showed more reduction of both systolic and diastolic BP compared to olmesartan .Safety profile was comparable. Quality of life appears slightly better with azilsartan.
Discussion: Many clinical trials also favours its superior efficacy. Azilsartan possesses very high affinity for angiotensin type II receptor (AT I R) with characteristically slow dissociation property Azilsartan also exhibits pleotropic effect making it better for cardio vascular and reno-protection.
Conclusion: Azilsartan is a novel angiotensin receptor blocker. It exhibits all the good quality of ARB with superior efficacy.
Keywords: angiotensin receptor blocker. azilsartan .olmesartan. clinic blood pressure. Clinical trials.
References
- Lawes CM, Vander Hoorn S, Rodgers A, International Society of Hypertension. Global burden of blood pressure related disease,2001. Lancet 2008;371:1513
- Kannel WB, Wolf PA. Framingham Study insights on the hazards of elevated blood pressure. JAMA 2008;300:2545
- Egan BM, ZhaoY, Axon RN: US trends in prevalence, awareness, treatment and control of hypertension, 1988-2008. JAMA.2010, 303 (20):2043-2050
- Llyod- Jones DM , Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA 2005; 294:466
- Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension. Eur Heart J. 2013;34:2159-2219 { PubMed}
- Jones JD, Jaction SH, Agboton C, Martin TS. Azilsartan medoxomil (Edarbi): the eight angiotensin II receptor blocker. PT2011; 36:6348
- Appel GB, Appel AS. Angiotensin Receptor Antagonists: Role in Hypertension, Cardiovascular Disease, and Renoprotection. Prog Cardiovasc Dis. 2004;47: 105-15.
- Zaiken K et al. Azilsartan medoxomil: a new Angiotensin receptor blocker. ClinTher2011;33:1577-899.
- Ojima M, Igata H, Tanaka m, et al. In vitro antagonistic properties of a new angiotensin type receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther. 2011; 336(3):801-808
- Nakamura Y, Suzuki S, Saitoh S, Takeishi Y. New angiotensin II type 1 receptor blocker, azilsartan, attenuates cardiac remodelling after myocardial infarction. Biol Pharm Bull. 2013; 36(8)
- Sica D, Bakeris GL, White WB, et al. Blood pressure lowering efficacy of the fixed dose combination of azilsartan and chorthalidone:: a factorial study. J ClinHypertens. 2012;14(5) 284-292.
- Weber MA, White WB, Sica D, et al. Effects of combining azilasartan with amlodipine in patients with stage 2 hypertension. Blood Press Monit. 2014;19: 90 - 97
- William B White et al-Effects of ARB Azilsartan medoxomil verses olmesartan and valsartan on Ambulatory and Clinic Blood Pressurein Patients With Stage 1 and Stage 2 hypertension. Hypertension, 2011:57:413-20
- Bakris GL: The comparative effects of azilsartan medoxomil and olmesartan on ambulatory blood pressure. Clin Hypertens 2011; 13:81-8
- Takagi H, Mizuno Y, Niwa M, Goto SN. Umemoto T. A meta-analysis of randamized controlled trials of azilsartan therapy for blood pressure reduction. Hypertens Res. 2014;37:432-437.